139 related articles for article (PubMed ID: 31566408)
41. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
42. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
43. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
Kim S; Abou-Alfa GK
Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
45. Are there indications for chemotherapy in hepatocellular carcinoma?
Johnson PJ
Surg Oncol Clin N Am; 2003 Jan; 12(1):127-34. PubMed ID: 12735134
[TBL] [Abstract][Full Text] [Related]
46. Regorafenib as treatment for patients with advanced hepatocellular cancer.
Thillai K; Srikandarajah K; Ross P
Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
[TBL] [Abstract][Full Text] [Related]
47. Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Meyer T
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):218-220. PubMed ID: 29533189
[No Abstract] [Full Text] [Related]
48. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
49. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
Bouattour M; Rousseau B; Wassermann J; Payancé A; Huillard O
J Clin Oncol; 2015 Aug; 33(22):2484-5. PubMed ID: 26033820
[No Abstract] [Full Text] [Related]
50. Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Mazzoccoli G; Miele L; Oben J; Grieco A; Vinciguerra M
Curr Drug Targets; 2016; 17(7):783-99. PubMed ID: 26648069
[TBL] [Abstract][Full Text] [Related]
51. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Montella L; Palmieri G; Addeo R; Del Prete S
World J Gastroenterol; 2016 Jul; 22(27):6114-26. PubMed ID: 27468204
[TBL] [Abstract][Full Text] [Related]
52. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Wang M; Wu M; Yang T
EBioMedicine; 2019 Feb; 40():11-12. PubMed ID: 30651221
[No Abstract] [Full Text] [Related]
53. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
54. Developing better treatments in hepatocellular carcinoma.
Duffy A; Greten T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
[TBL] [Abstract][Full Text] [Related]
55. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Facciorusso A; Licinio R; Carr BI; Di Leo A; Barone M
Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):993-1003. PubMed ID: 25915713
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
57. Systemic therapy for advanced hepatocellular carcinoma: a review.
Nowak AK; Chow PK; Findlay M
Eur J Cancer; 2004 Jul; 40(10):1474-84. PubMed ID: 15196530
[TBL] [Abstract][Full Text] [Related]
58. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
59. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.
Mehdizadeh A; Somi MH; Darabi M; Jabbarpour-Bonyadi M
Mol Biol Rep; 2016 Feb; 43(2):107-16. PubMed ID: 26767647
[TBL] [Abstract][Full Text] [Related]
60. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells.
Wang H; Zuo B; Wang H; Ren L; Yang P; Zeng M; Duan D; Liu C; Li M
Biochem Biophys Res Commun; 2012 May; 422(1):103-8. PubMed ID: 22564734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
